Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy

Qiu, Chong1; Wu, Yanyan2; Shi, Qiaoli1; Guo, Qiuyan1; Zhang, Junzhe1; Meng, Yuqing1; Wang, Chen1; Xia, Fei1; Wang, Jigang1,3,5; Xu, Chengchao1,4

2023

10.7150/ijbs.79328

International Journal of Biological Sciences   影响因子和分区

1449-2288

Cancer has been considered as complex malignant consequence of genetic mutations that control the cellular proliferation, differentiation and homeostasis, thus making tumor treatment extremely challenging. To date, a variety of cargo molecules, including nucleic acids drugs (pDNA, miRNA and siRNA), therapeutic drugs (doxorubicin, paclitaxel, daunomycin and gefitinib) and imaging agents (radioisotopes, fluorescence dyes, and MRI contrast agents) have been regarded as the potential medicines in clinical application. However, non-single therapeutic drug could induce the satisfied clinical results because of tumor heterogeneity and multiple drug resistance and the nanotechnology-based combined therapy is becoming an advanced important mode for enhanced anticancer effects. The review gathers the current advanced development to co-deliver small-molecular drugs and nucleic acids for the anticancer therapy with nanomedicine-based combination. Furthermore, the superiority is definitely presented and the barriers are detail discussed to surmount the clinical challenges. In final, future perspectives in rational direction for combined tumor therapy of drugs and nucleic acids are exhibited.

anticancer nucleic acids small-molecular drugs combination synergistic therapy

SCI

英语

通讯

Fundamental Research Funds for the National Natural Science Foundation["82204322","82141001","82074098","8227 4182"] ; Beijing Natural Science Foundation[7214287] ; Central Public Welfare Research Institutes["ZZ14-YQ-050","ZZ14-YQ-051","ZZ14-YQ-055","ZZ14-YQ-058","ZZ14-YQ-059","ZZ14-YQ-061","ZZ14-ND-010","ZZ15-ND-10","ZZ14-FL-002"] ; National Key Research and Development Program of China[2020YFA0908000] ; National Key R&D Program of China Key projects for international cooperation on science, technology and innovation[2020YFE0205100] ; CACMS Innovation Fund["CI2021A05104","CI2021B014"] ; Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences[ZYYCXTD-C-202002] ; null[CI2021A 05101]

Biochemistry & Molecular Biology ; Life Sciences & Biomedicine - Other Topics

Biochemistry & Molecular Biology ; Biology

WOS:000935312600004

IVYSPRING INT PUBL

Web of Science

1.China Acad Chinese Med Sci, Inst Chinese Mat Med, Artemisinin Res Ctr, Beijing 100700, Peoples R China
2.Chinese Acad Med Sci & Peking Union Med Coll, Beijing 100730, Peoples R China
3.Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Peoples R China
4.Fujian Univ Tradit Chinese Med, Coll Integrat Med, Lab Pathophysiol, Key Lab Integrat Med Chron Dis, Fuzhou 350122, Peoples R China
5.Southern Univ Sci & Technol, Shenzhen Peoples Hosp, Affiliated Hosp 1, Shenzhen Clin Res Ctr Geriatr, Shenzhen 518020, Peoples R China

Qiu, Chong,Wu, Yanyan,Shi, Qiaoli,et al. Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy[J]. International Journal of Biological Sciences,2023,19(3).

Qiu, Chong.,Wu, Yanyan.,Shi, Qiaoli.,Guo, Qiuyan.,Zhang, Junzhe.,...&Xu, Chengchao.(2023).Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy.International Journal of Biological Sciences,19(3).

Qiu, Chong,et al."Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy".International Journal of Biological Sciences 19.3(2023).